We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04430374
Recruitment Status : Unknown
Verified June 2020 by Dr. JASSIM MOHD. AL SUWAIDI, Hamad Medical Corporation.
Recruitment status was:  Recruiting
First Posted : June 12, 2020
Last Update Posted : June 26, 2020
Information provided by (Responsible Party):
Dr. JASSIM MOHD. AL SUWAIDI, Hamad Medical Corporation

Brief Summary:
The novel coronavirus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID -19), is highly contagious in the community and has resulted in a global pandemic. This infection has a special implication on the patient who complains from cardiac disease or acute cardiovascular condition and may result in cardiovascular complications such as myocardial infarction. For this end, we target to study this group of patient, who has a cardiac disease with COVID-19 in Qatar, in addition, the acute myocardial infarction with COVID-19 from the Gulf countries and collect all the related data to come with a comprehensive view about those patients.

Condition or disease Intervention/treatment
Cardiovascular Diseases Other: No interverntion

Show Show detailed description

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 1 Week
Official Title: Qatar Cardiovascular COVID-19 Registry
Actual Study Start Date : June 2, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

Intervention Details:
  • Other: No interverntion
    No intervention will be done, registry only

Primary Outcome Measures :
  1. The impact of COVID-19 on cardiovascular patient [ Time Frame: 2 month from starting date ]

    The outcome of this registry will be:

    • entire information about the patients who admitted with COVID-19 accompany with a cardiovascular condition in Qatar.
    • Additionally, a comparison will be conducted between the cardiac patient who admitted over the period February to December to December 2020 and the same category of patients over the same period of 2019 in Qatar to figure out the reason behind the dropping of the number of the patient.
    • A multicenter data from the Gulf countries for Acute MI patients infected with COVID-19.
    • A comparison between our patients (either in Qatar only or the entire Gulf) populations and the outcome of other international registries such as the NACMI (US registry)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
(1) Retrospective data for all patients since the COVID-19 appear in Qatar unit the prospective arm gets started after approval(2) Prospective data starting from the date of submission of this protocol and forward and all patients will be followed up for long-term outcome(3) Retrospective data for all cardiac patients hospitalizations in the COVID period of this year 2020 will be compared to previous years to report the trends of acute cardiovascular conditions in the COVID era to previous data, as a lot of countries documented decrease in the incidence.

Inclusion Criteria:

  1. Patients who admitted to the heart hospital or any other hospital with acute cardiovascular condition.
  2. Patient with confirming or suspicious of COVID-19 infection
  3. Patient who admitted to any hospital in the Gulf and has Acute MI with confirm or suspicious of COVID-19 infection

Exclusion Criteria:

  • N/A

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04430374

Layout table for location contacts
Contact: MRC 44396168 MRC@hamad.qa

Layout table for location information
Hamad Medical Corporation Recruiting
Doha, Unlisted (UL), Qatar, 974
Contact: DR.Jassim Alsuwaidi Senior Consultant    44395392    jalsuwaidi@hamad.qa   
Sponsors and Collaborators
Hamad Medical Corporation
Layout table for investigator information
Principal Investigator: Dr.Jassim Alsuwaidi Senior Consultant HMC
Layout table for additonal information
Responsible Party: Dr. JASSIM MOHD. AL SUWAIDI, Senior Cardiologist, Hamad Medical Corporation
ClinicalTrials.gov Identifier: NCT04430374    
Other Study ID Numbers: MRC-05-113
First Posted: June 12, 2020    Key Record Dates
Last Update Posted: June 26, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases